Newland Pharmaceutical Co., Ltd. (SHE:301277)

Market Cap	3.60B -24.0%
Revenue (ttm)	659.54M -13.4%
Net Income	100.78M -42.2%
EPS	0.26 -41.6%
Shares Out	392.08M
PE Ratio	35.67
Forward PE	n/a
Dividend	0.20 (2.16%)
Ex-Dividend Date	Apr 30, 2026

Volume	2,288,790
Open	9.16
Previous Close	9.28
Day's Range	9.03 - 9.31
52-Week Range	9.03 - 17.51
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Newland Pharmaceutical

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, l...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 981
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301277

Financial Performance

In 2025, Newland Pharmaceutical's revenue was 672.38 million, a decrease of -7.44% compared to the previous year's 726.44 million. Earnings were 121.25 million, a decrease of -30.17%.